Enzymatic generation of whey protein hydrolysates under pH-controlled and non pH-controlled conditions: Impact on physicochemical and bioactive properties.

Solène Le Maux,A. Nongonierma,C. Barre,R. Fitzgerald

DOI: https://doi.org/10.1016/j.foodchem.2015.12.021

IF: 8.8

2016-05-15

Food Chemistry

Abstract:

What problem does this paper attempt to address?

Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).

Lorenzo Gerratana,Andrew A. Davis,Marko Velimirovic,Paolo D'Amico,Ami N. Shah,Katherine Clifton,Qiang Zhang,Charles Sichao Dai,Carolina Reduzzi,Whitney L Hensing,Marta Bonotto,Roberta Mazzeo,Firas Hazem Wehbe,Alessandra Franzoni,Barbara Belletti,Amir Behdad,Cynthia X.,Fabio Puglisi,Aditya Bardia,Massimo Cristofanilli,Cynthia X. Ma

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.1033

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:1033 Background: The exposure to endocrine therapy (ET) can induce the onset of ESR1 gene alterations that have an impact on not only treatment resistance but also clinical phenotype. We previously demonstrated the potential of liquid biopsy in describing the metastatic behavior of MBC. The aim of this study was to explore the different clinical phenotype across the main ESR1 and PIK3CA codon variants. Methods: The study retrospectively analyzed a cohort of 501 MBC patients (pts) characterized for ctDNA through NGS before treatment start at Northwestern University (Chicago, IL), Massachusetts General Hospital (Boston, MA), CRO National Cancer Institute (Aviano, IT) and ASUFC Hospital (Udine, IT) between 2014 and 2020. Associations between clinical characteristics and ESR1 and PIK3CA codon variants were explored through logistic regression corrected for sites and ESR1/ PIK3CA status. Survival was tested through Cox regression both for progression-free survival (PFS) and overall survival (OS). Results: Of the total 501 pts, 289 (58%) were diagnosed with hormone-receptor positive (HRpos) MBC, 114 (23%) with HER2-positive MBC, and 93 (19%) with triple-negative MBC. ESR1 mutations were detected in 71 pts (14%) and PIK3CA in 154 pts (31%). The most represented ESR1 gene mutations were found in codons 380 (9%), 536 (23%), 537 (34%), and 538 (34%), while alterations in codons 542 (19%), 545 (21%), and 1047 (60%) were the most common for PIK3CA. As expected, ESR1 mutations were found only in HRpos pts previously exposed to ET (P < 0.001). No significant differences were observed for PIK3CA. After multivariable analysis, ESR1mutations were confirmed as highly associated with liver and bone metastases (OR 3.31, P < 0.001 and OR 5.09, P < 0.001). Moreover, an association with lung (OR 2.07, P = 0.010) was observed in this cohort. After multivariable analysis, codon 537 mutations were associated with bone involvement (OR 12.97, P = 0.014), codon 538 with liver (OR 4.73, P = 0.010), and codon 536 with soft tissue (OR 5.84, P = 0.006) and liver (OR 4.06, P = 0.048). PIK3CA mutations were associated with bone (OR 2.61, P < 0.001) and lung metastases (OR 1.62, P = 0.044). Specifically, codon 1047 mutations were the primary driver (OR 3.14, P = 0.001 and OR 1.97, P = 0.019). In HRpos MBC, baseline mutations in ESR1 codon 537 and 538 had a negative impact on OS (HR 3.73, P < 0.010 and HR 2.99, P < 0.021), while 380 and 536 had a negative impact on PFS (HR 18.98, P < 0.001 and HR 2.60, P = 0.015). No impact was observed across PIK3CA gene variants. Conclusions: This study showed the different tumor biology across ESR1 and PIK3CA gene variants. As novel selective estrogen receptor degraders (SERDS) and PIK3CA inhibitors are gaining momentum as new ET options in MBC, these results highlight the future pivotal role of ctDNA NGS in refining tumor biology characterization.

oncology
Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.

Jesus Fuentes Antras,Mitchell Elliott,Sasha Main,Philippe Echelard,Aaron Dou,Philippe L. Bedard,Eitan Amir,Michelle B. Nadler,Nancy Gregorio,Elizabeth Shah,Emily Van de Laar,Celeste Yu,Lisa Gates,Clodagh Murray,Christopher Gareth Smith,Amber Chevalier,Scott Victor Bratman,Lillian L. Siu,Hal K. Berman,David W. Cescon

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3052

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:3052 Background: Tumor-informed circulating tumor DNA (ctDNA) assays, designed to track patient (pt) specific variants identified by tumor sequencing, offer enhanced sensitivity compared to traditional assays focused on driver genes. This approach enables precise ctDNA quantification, facilitating early detection of molecular progression and innovative strategies in metastatic breast cancer (mBC). Methods: HR+/HER2- mBC pts receiving standard endocrine therapy + CDK4/6 inhibitors (CDKi) were enrolled in a prospective observational cohort (2018–2023). Plasma samples were collected at baseline (BL), within 30 days (d) and ~q3 months with restaging scans. Archival tumor WES was used to design personalized panels for ctDNA monitoring. The primary endpoint was time to treatment failure (TTF). Results: Of 51 pts analyzed (median age 60 years [range 38-88], 1/2L [75/20%], visceral disease 63%, palbo-/ribo-/abemaciclib 76/22/2%), tumor-informed panels were successfully designed for 43 (1 failed WES, 7 failed QC), detecting BL ctDNA in 39 (91%). The median BL estimated variant allele fraction (eVAF) was 0.5% (0.006–17.9) and was associated with liver metastases but no other covariates (e.g. bone-only disease, history of 1ry endocrine resistance [ER]). Higher BL eVAF predicted shorter TTF (HR 1.14 CI 95% 1.05–1.23, p1, >0.5 and <0.5 at any timepoint had median lead times to TF of 76 d (Q1–Q3 25–135), 133 d (41–360), and 326 d (174–471). A complete analysis of ctDNA dynamics and operating parameters will be presented along with RECIST 1.1 evaluation and WES-based genomic subgroups. Conclusions: ctDNA levels and changes on therapy are prognostic and high sensitivity tumor-informed assays expand the proportion of pts who can be monitored. ctDNA clearance identified pts with better outcome and might inform pt follow up and interventional strategies. Reappraisal of existing early response cutoffs, with limited precision for individual decision making, may be necessary with more sensitive assays.

oncology
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.

Mitchell Elliott,Jesus Fuentes Antras,Sasha Main,Aaron Dou,Nancy Gregorio,Elizabeth Shah,Emily Van de Laar,Geethika Yalamanchili,Leylah Drusbosky,Caroline M. Weipert,Eitan Amir,Michelle B. Nadler,Celeste Yu,Hal K. Berman,Lillian L. Siu,Philippe L. Bedard,David W. Cescon

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1043

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:1043 Background: CDK4/6-inhibitors (-i) and endocrine therapy (ET) are first-line treatment for HR+/HER2- metastatic breast cancer (mBC). Clinical evaluation and cross-sectional imaging are used for treatment response assessment. The relationship between clinical/radiographic response and ctDNA dynamics using a high sensitivity tumor-agnostic assay is unknown in HR+/HER2- mBC. ctDNA monitoring in mBC may support clinical decision-making, enable new strategies for response assessment in clinical trials, and facilitate enrolment of patients lacking measurable disease (bone-only). Methods: Patients (pts) with HR+/HER2- mBC receiving ET and CDK4/6i were enrolled in a prospective cohort study. Plasma samples were collected at baseline (BL) and regularly on-treatment. Samples were analyzed using Guardant Infinity, a tumor-agnostic genomic and epigenomic platform. ctDNA-response (-R) was defined as a ≥50% decrease (dec) in methylation tumor fraction (mTF) from BL. ctDNA-progression (-P) was defined as a <50% dec in mTF from BL or any subsequent increase in mTF above an absolute mTF of 0.001% (cohort specific definition). Imaging outcomes and dates of treatment discontinuation (TD) were collected. Results: 57 pts with 350 clinical timepoints were evaluated. Median follow up was 28.2m (range: 1.6-66.0m). 42/57 (74%) pts received palbociclib and 40/57 (70%) received an aromatase inhibitor. ctDNA-R/-P was evaluable in 49/57 patients. ctDNA-P identified within the first 90d on CDK4/6i was not prognostic of TD (p=0.7972); when assessed between 90-180d it was prognostic of early TD (med: 6.3m vs. not reached; HR: 5.17, 95%CI: 1.04-25.7; p=0.0003). 156 matched radiographic and ctDNA assessments (blood collected within 30d of CT) were evaluable for ctDNA-R/-P and imaging concordance. Excluding those with clinician-identified sclerotic bone changes suggestive of treatment effect (n=5 events), adjudicated radiographic progression did not occur in the setting of ctDNA-R (NPV: 100%, sensitivity: 100%); no pts had clinical progression in the presence of ctDNA-R. ctDNA rise in the absence of radiographic progression occurred in 13 pts; 7/13 had TD (med: 10.1m, range: 3.0-21.9m) in the follow up period reflecting a molecular lead time. Blood first monitoring, using these metrics, could have avoided 104/150 (69%) staging CT scans in this cohort. Conclusions: ctDNA dynamics are associated with clinical outcomes in HR+/HER2- mBC. The use of a high sensitivity assay permits assessment of response in nearly all patients and suggests the possibility that radiographic surveillance could be reduced in patients with ctDNA-R. Prospective validation of these findings are required. Additional ctDNA-R/-P definitions and relationship with RECIST 1.1 criteria will be presented at the meeting.

oncology
Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Andi K. Cani,Emily M. Dolce,Elizabeth P. Darga,Kevin Hu,Chia‐Jen Liu,Jackie Pierce,Kieran Bradbury,Elaine Kilgour,Kimberly Aung,Gaia Schiavon,Danielle Carroll,T. Hedley Carr,Teresa Klinowska,Justin Lindemann,Gayle Marshall,Vicky Rowlands,Elizabeth A. Harrington,J. Carl Barrett,Nitharsan Sathiyayogan,Christopher Morrow,Valeria Sero,Anne C. Armstrong,Richard Baird,Erika Hamilton,Seock‐Ah Im,Komal Jhaveri,Manish R. Patel,Caroline Dive,Scott A. Tomlins,Aaron M. Udager,Daniel F. Hayes,Costanza Paoletti

DOI: https://doi.org/10.1002/1878-0261.13150

2021-12-20

Molecular Oncology

Abstract:Nearly all estrogen receptor (ER)-positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events associated with response/progression by serial tissue biopsies is logistically difficult. Use of liquid biopsies, including circulating tumor cells (CTC) and circulating tumor DNA (ctDNA), might provide highly informative, yet easily obtainable, evidence for better precision oncology care. Although ctDNA profiling has been well investigated, the CTC precision oncology genomic landscape and the advantages it may offer over ctDNA in ER-POS breast cancer remain largely unexplored. Whole-blood (WB) specimens were collected at serial time points from patients with advanced ER-POS/HER2-negative (NEG) advanced breast cancer in a phase I trial of AZD9496, an oral selective ER degrader (SERD) ET. Individual CTC were isolated from WB using tandem CellSearch<sup>®</sup> /DEPArray™ technologies and genomically profiled by targeted single-cell DNA next-generation sequencing (scNGS). High-quality CTC (n = 123) from 12 patients profiled by scNGS showed 100% concordance with ctDNA detection of driver estrogen receptor α (ESR1) mutations. We developed a novel CTC-based framework for precision medicine actionability reporting (MI-CTCseq) that incorporates novel features, such as clonal predominance and zygosity of targetable alterations, both unambiguously identifiable in CTC compared to ctDNA. Thus, we nominated opportunities for targeted therapies in 73% of patients, directed at alterations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), fibroblast growth factor receptor 2 (FGFR2), and KIT proto-oncogene, receptor tyrosine kinase (KIT). Intrapatient, inter-CTC genomic heterogeneity was observed, at times between time points, in subclonal alterations. Our analysis suggests that serial monitoring of the CTC genome is feasible and should enable real-time tracking of tumor evolution during progression, permitting more combination precision medicine interventions.

oncology
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Lorenzo Gerratana,Andrew A. Davis,Marko Velimirovic,Katherine Clifton,Whitney L. Hensing,Ami N. Shah,Charles S. Dai,Carolina Reduzzi,Paolo D’Amico,Firas Wehbe,Arielle Medford,Seth A. Wander,William J. Gradishar,Amir Behdad,Fabio Puglisi,Cynthia X. Ma,Aditya Bardia,Massimo Cristofanilli,Paolo D'Amico,Cynthia X. Ma…

DOI: https://doi.org/10.1186/s13058-023-01718-0

2023-10-03

Breast Cancer Research

Abstract:although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice.

oncology
Diagnostic utility of ESR1 mutation detection in liquid biopsy of metastatic breast cancer patients

Maria Sandbothe,Britta Hasemeier,Elisa Schipper,Nora Schaumann,Hans Kreipe,Ulrich Lehmann,Stephan Bartels

DOI: https://doi.org/10.1007/s00428-024-03942-1

2024-10-11

Abstract:Molecular analysis of circulating cell-free DNA (cfDNA) extracted from peripheral blood plasma samples of metastatic breast cancer (BC) patients is of rising interest to find optimal therapeutic strategies. Detection of emerging resistance mutations against endocrine therapy is possible with this approach. Here we present the applicability of a laboratory-developed NGS assay in molecular pathology routine diagnostic, covering four genes with therapeutic (ESR1, PIK3CA, ERBB2) and prognostic (TP53) consequences in metastatic BC. We analyzed 162 liquid biopsy samples and 25 corresponding metastases from metastatic BC patients. In the liquid biopsies, we detected ESR1 mutations in 42 cases (25.9%) and ERBB2 mutations in six cases (3.7%), arguing for a change in therapy to fulvestrant, elacestrant, or neratinib. Furthermore, 17 cases had detectable TP53 mutations, associated with resistance against endocrine therapy. We conclude that liquid biopsy testing is a noninvasive, sensitive, and helpful method to optimize therapeutic decisions in metastatic BC.
Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Jeffrey A. How,Amir A. Jazaeri,Bryan Fellman,Molly S. Daniels,Suzanna Penn,Cara Solimeno,Ying Yuan,Kathleen Schmeler,Jerry S. Lanchbury,Kirsten Timms,Karen H. Lu,Melinda S. Yates

DOI: https://doi.org/10.3390/cancers13050946

2021-01-01

Cancers

Abstract:New therapies, such as poly-ADP ribose polymerase inhibitors (PARPi), and immunotherapy treatments have generated great interest in enhancing individualized molecular profiling of epithelial ovarian cancer (EOC) to improve management of the disease. In EOC patients, putative biomarkers for homologous recombination deficiency (HRD), microsatellite instability (MSI), and tumor mutational burden (TMB) were characterized and correlated with survival outcomes. A series of 300 consecutive EOC patients were enrolled. Patients underwent neoadjuvant chemotherapy (n = 172) or primary cytoreductive surgery (n = 128). Molecular profiling and survival analyses were restricted to the primary cytoreductive surgery cohort due to tissue availability. All patients underwent germline testing for HRD- and MSI-related gene mutations. When sufficient tissue was available, screening for somatic BRCA1/2 mutations, BRCA1 promoter methylation, HRD score (a measure of genomic instability), MSI, and TMB testing were performed. HRD score ≥33 was associated with improved overall survival on multivariable analysis. In the era of biomarker-driven clinical care, HRD score ≥33 may be a useful adjunctive prognostic tool and should be evaluated in future studies to predict PARPi benefits.
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).

Panagiotis A. Konstantinopoulos,Mingyang Cai,Elizabeth Katherine Lee,Niya Xiong,Carolyn N. Krasner,Susana M. Campos,Joyce F. Liu,Neil S. Horowitz,Alexi A. Wright,Meghan Shea,Sara Bouberhan,Richard T. Penson,Oladapo O. Yeku,Hannah Sawyer,Martin Hayes,Madeline Polak,Cesar Martin Castro,SuChun Cheng,Caroline M. Weipert,Ursula A. Matulonis

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5592

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:5592 Background: In a phase 2 study, letrozole/abemaciclib demonstrated an objective response rate (ORR) of 30% and median progression free survival (PFS) of 9.1 months in recurrent ER positive EC. While tissue-based tumor profiling revealed several mechanistically relevant candidate baseline genomic predictors of response ( CTNNB1, KRAS,and CDKN2A mutations) and absence of response ( TP53mutations), circulating tumor DNA (ctDNA) is a less invasive alternative to monitor therapeutic efficacy and define acquired resistance. Methods: Serial plasma specimens were obtained at baseline, cycle 2 day 1 (C2D1), C3D1, C8D1, time of objective response, and at the time of progression from participants who consented for this optional collection. Samples were analyzed using the Guardant Infinity assay, which includes genotyping of > 750 genes and methylation-based tumor fraction (TF). Treatment response was assessed using the Guardant methylation-informed Molecular Response algorithm. Patients with 50% or more decrease in ctDNA levels or with absolute low ctDNA levels were defined as achieving Molecular Response (MR). Comparison of survival curves was performed using the logrank test. Results: 99/102(97%) samples from 28 patients were successfully analyzed. Three samples were excluded from analysis for not meeting sequencing quality control thresholds. Detection of ctDNA at baseline, measured via methylation-based TF, was associated with worse median PFS, (ctDNA detected (n = 18): 3.5 months vs ctDNA undetected (n = 8): 16.5 months, p = 0.006, HR = 12.5) and overall survival (OS), (ctDNA detected: 11.6 months vs ctDNA undetected: not yet reached, p = 0.008, HR = 4.7e7). Patients who achieved MR after the first or second cycle of letrozole/abemaciclib therapy exhibited better median PFS (MR(n = 13): 12.8 vs not-MR(n = 10): 3.5 months, p < 0.001, HR = 0.1) and were more likely to demonstrate clinical benefit (objective response and/or progression free survival for ≥6 months) from this regimen (MR: 84.6% vs not-MR: 10.0%, p < 0.001, odds ratio (OR) = 49.5). ctDNA analysis of post-progression specimens identified several acquired genomic alterations associated with resistance to combined aromatase/CDK4&6 inhibitor therapy, such as ESR1 mutations/amplification, RB1 mutations, ERBB2 amplification/mutations and CCNE1 amplification. Of note, 2 of the 3 patients with mismatch repair deficient (dMMR) ECs acquired ESR1 mutations at the time of progression; both patients had exhibited durable objective responses to therapy. Conclusions: Baseline and on-treatment ctDNA dynamics may provide an early indication of long-term outcomes and benefit from letrozole/abemaciclib in EC. ctDNA at the time of progression may identify genomic alterations of acquired resistance (such as ESR1, RB1, CCNE1,and ERBB2 alterations) that may guide selection of subsequent therapy.

oncology
Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial

Andi K. Cani,Emily M. Dolce,Elizabeth P. Darga,Kevin Hu,Martha Brown,Chia-Jen Liu,Jackie Pierce,Kieran Bradbury,Kimberly Aung,Gaia Schiavon,Danielle Carroll,T. H. Carr,Teresa Klinowska,Justin Lindemann,Gayle Marshall,Vicky Rowlands,Elizabeth A. Harrington,J. Barrett,Anne Armstrong,Richard Baird,Erika Hamilton,Seock-Ah Im,Komal Jhaveri,Manish R. Patel,Caroline Dive,Scott A. Tomlins,Aaron M. Udager,Daniel F. Hayes,Costanza Paoletti

DOI: https://doi.org/10.1158/1538-7445.am2021-3143

IF: 11.2

2021-07-01

Cancer Research

Abstract:Abstract Purpose: The vast majority of advanced ER POS breast cancers eventually cease responding to endocrine (ET) and other therapies leading to evolution of lethal disease. However, timely monitoring of the molecular events associated with response/progression in tissue biopsies is logistically difficult. The use of liquid biopsies, such as CTC and ctDNA, in this context has been of recent interest. Patients and Methods: Individual CTC and ctDNA were obtained at different time points from patients with advanced ER POS/HER2 NEG breast cancer enrolled in a Phase I trial of AZD9496, an oral selective estrogen receptor degrader (SERD) ET. The CTC, purified using tandem CellSearch®/DepArrayTM technologies, were genomically profiled by DNA single cell next generation sequencing (scNGS). Plasma ctDNA was isolated from blood collected in Streck BCT tubes. Genomic profiling was performed by targeted gene panel scNGS for CTC and ddPCR for ERα gene (ESR1) mutations in ctDNA. Results: 123 high-quality CTCs from 12 patients profiled by scNGS showed 100% concordance with ctDNA in detection of driver ESR1 somatic mutations. CTC scNGS additionally revealed extensive intra-patient heterogeneity of driver alterations, that would have been unresolvable by bulk ctDNA profiling, including separate subclonal CTC populations emerging within the same patient. ScNGS revealed potential opportunities for targeted therapies in 73% of patients, directed at alterations in PIK3CA, FGFR2, KIT and BRAF, at times present as 2 or more targets in the same or different cell populations. In one patient, an emergent, distinct, BRAF p.V600E targetable alteration was detected in a subpopulation of CTCs collected at the progression time point but not at baseline. Conclusion: Serial monitoring of CTC and ctDNA genomic alterations is feasible and should enable real-time tracking of response/progression, tumor evolution and opportunities for precision medicine interventions. Citation Format: Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Martha Brown, Chia-Jen Liu, Jackie Pierce, Kieran Bradbury, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. H. Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Barrett, Anne Armstrong, Richard Baird, Erika Hamilton, Seock-Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti. Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3143.

oncology
ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).

Qiang Zhang,Weijun Qin,Jianhua Jiao,Andrew A. Davis,Lorenzo Gerratana,Jeannine Donahue,Carolina Reduzzi,Marwa Manai,Saya Jacob,Youbin Zhang,Lisa E. Flaum,Amir Behdad,Massimo Cristofanilli,Leonidas C. Platanias,Ami N. Shah,William John Gradishar,Paolo D'Amico

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.1057

IF: 45.3

2022-06-04

Journal of Clinical Oncology

Abstract:1057 Background: The monitoring of ctDNA and circulating tumor cells (CTCs) in patients with MBC predicts metastasis and prognosis. We previously reported that HER2 and ESR1 alterations in ctDNA were associated with predicted metastasis in MBC (2019 ASCO#1036). Furthermore, ctDNA can be used to evaluate tumor heterogeneity (2020 ASCO #1028). Here, we report that baseline ctDNA ESR1 mutation is a key point associated with tumor tissue characteristics and CTCs, which may help to elucidate disease resistance in MBC. Methods: This study included 288 hormone receptors positive MBC patients who received systemic treatment under an IRB-approved clinical trial (NU16B06) at NU Lurie Cancer Center (2016-2021). Baseline plasma ctDNA was analyzed by Guardant360 NGS for ESR1 mutations. CTC enumerations were performed by using 7.5ml blood in CELLTRACKS (Menarini). Estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67 in each patient's biopsy tumor tissue before surgery, surgical tumor tissue and metastatic tumor tissue were evaluated by NU PathCore. Kruskal-Wallis was used for statistics. Results: Of the 288 patients, ESR1 mutations were found in 18 hotspots from 38 patients (ESR1 Mut , 13.19%) and there were 250 patients without any mutation (ESR1 WT , 86.81%). Median of Total CTCs (/7.5ml) and HER2 + CTCs (/7.5ml) were significantly increased in ESR1 Mut group compared to ESR1 WT group, total CTCs were 8.0 vs 1.0 (P=0.006) and HER2 + CTCs were 1.5 vs 0 (P=0.014), respectively. There were significant differences on hormone receptors expression (positive cells %) in tumor tissues between ESR1 Mut group and ESR1 WT group: 1) ESR1 Mut group has significant higher expression in ER and PR in biopsy tumor tissues. The mean of ER in ESR1 + group was 90.48% vs 48.18% in ESR1 WT group (p<0.001). The mean of PR in ESR1 Mut group was 40.86% vs 25.60% in ESR1 WT group (p<0.001). Meanwhile, there is not significant difference on HER2 expression in ESR1 Mut group compared ESR1 WT group; 2) In the surgical tumor tissues, the mean ER was 97.64% in ESR1 Mut group which was significantly higher than 47.90% in ESR1 WT group (p<0.001), while the PR was 45.33% and 24.32%, respectively; 3) In metastatic tumor tissues, the mean of ER in ESR1 Mut group was 84.75% vs 34.89% in ESR1 WT group (p<0.001) and the mean of PR in ESR1 Mut group was 32.25% vs 9.33% in ESR1 WT group (p<0.001). Furthermore, median of Ki67 in ESR1 Mut group is 28.33% which was significantly higher than 18.75% in ESR1 WT group (p<0.01). Conclusions: Baseline ctDNA ESR1 mutations not only had higher total CTCs and HER2 + CTCs but also significantly correlated with high hormone receptors and proliferation in tumor metastatic tumor tissues. The synergy of ctDNA ESR1 mutation and tissue pathological characteristics expands the early predictive role of ctDNA monitoring metastatic prognosis for clinical decision-making.

oncology
THE ART OF NURSING

V. Aita

DOI: https://doi.org/10.1097/00006223-199011000-00011

1990-11-01

Nurse Educator

Abstract:The author presents a framework for artistic nursing practice that fits within the nursing process and balances scientific principles with artistic concepts. The framework can be used by nurse educators to help them teach the qualitative aspects of nursing care. In addition, artistic concepts which relate to the nursing process, including vision, composition, theme, perspective, congruency, line, color, tone, style, technique, and intensity are discussed.
Leucine metabolism in rats with cirrhosis.

M. Holeček,I. Tilšer,F. Skopec,L. Šprongl

DOI: https://doi.org/10.1016/S0168-8278(96)80031-6

IF: 25.7

1996-02-01

Journal of Hepatology

Abstract:
Abstract 3676: A circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer

Michelle M. Stein,Kristiyana Kaneva,Seung Won Hyun,Chithra Sangli,Michelle Ting-Lin,Rotem Ben-Shachar,Jonathan Freaney,Kate Sasser,Justin Guinney,Halla Nimeiri,Massimo Cristofanilli

DOI: https://doi.org/10.1158/1538-7445.am2024-3676

IF: 11.2

2024-03-23

Cancer Research

Abstract:Background: ESR1 mutations (ESR1m) are acquired resistance mutations that evolve during treatment with aromatase inhibitor (AI) therapy in approximately 40% of ER+ HER2- metastatic breast cancer (mBC) patients and are indicative of poor outcomes. Patients with ESR1m acquired on AI may retain treatment response if switched to selective estrogen receptor degraders (SERDs) like fulvestrant. Circulating tumor DNA (ctDNA) analysis can detect the emergence of ESR1 mutations and simultaneously determine molecular response to therapy through changes in quantitative ctDNA tumor fraction (ctDNA TF). We used real-world data (RWD) to study the combined effect of acquired ESR1 mutation status and ctDNA TF dynamics on overall survival in ER+ HER2- mBC. Methods: Tempus xF Monitor is a ctDNA assay that measures quantitative molecular changes in ctDNA TF by utilizing diverse genomic events, dynamically weighting somatic variant allele frequencies and copy number variants, while using germline information to inform these estimates and providing single nucleotide variant (SNV) results on 105 genes including ESR1. Non-responders (NR) were characterized as < 50% reduction in ctDNA TF while responders (MR) experienced ≥ 50% reduction in ctDNA TF. We selected a cohort from the deidentified Tempus multimodal database of 101 HR+ HER- mBC patients with a baseline xF test up to one year prior to or 3 months post AI therapy start. Real-world overall survival (rwOS) was defined as the interval from AI start to death, censored on the last known physician follow-up. Kaplan Meier analysis and Cox proportional hazards models were fitted to evaluate the relationship between ESR1m and MR/NR status with rwOS. Results: In our evaluable cohort, (n=101), median age 59, ESR1m was detected in 29.7% (n=30) patients. ESR1m patients had shorter rwOS compared to ESR1 WT patients (median ESR1m rwOS 63.8 months, median rwOS not reached for ESR1 WT; p=0.013, HR=3.45 [1.9-9.2]). Across the cohort, regardless of ESR1 status, 23.8% (24/101) of patients were characterized as ΔctDNA TF MR, 60.4% (61/101) as NR and 15.8% (16/101) of patients with ctDNA TF values below the limit of blank (b-LOB). Within the NR group, 35.5% (22/61) were also ESR1m, while only 20.8% (5/24) and 18.8% (3/16) ESR1m patients were in the MR and b-LOB group, respectively. Patients with combined ESR1m + NR ΔctDNA TF (n=22) experienced shorter rwOS (p=0.015) compared to MR ΔctDNA TF patients with WT ESR1 (p=0.024, HR=6.61 [1.3-34.2]). Conclusions: xF Monitor is a ctDNA assay that tracks changes in quantitative ctDNA TF and simultaneously monitors for the emergence of ESR1m, providing a diagnostic that identifies resistance to AI therapy and enables early switch to therapies that could improve outcomes in a patient population with poor prognosis. A larger prospective clinical study is needed to validate these findings. Citation Format: Michelle M. Stein, Kristiyana Kaneva, Seung Won Hyun, Chithra Sangli, Michelle Ting-Lin, Rotem Ben-Shachar, Jonathan Freaney, Kate Sasser, Justin Guinney, Halla Nimeiri, Massimo Cristofanilli. A circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3676.

oncology
Abstract PS06-09: Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies

Kyle Helzer,Jamie Sperger,Yue Shi,Viridiana Carreno,Hannah Krause,Katherine Kaufmann,Leilani Mora-Rodriguez,Matthew Bootsma,Mark Burkard,Ruth O'Regan,Kari Wisinski,Joshua Lang,Shuang (George) Zhao,Malinda West,Marina Sharifi

DOI: https://doi.org/10.1158/1538-7445.sabcs23-ps06-09

IF: 11.2

2024-05-03

Cancer Research

Abstract:Background: Circulating tumor DNA (ctDNA) isolated from the peripheral blood of patients with cancer is now routinely used in the clinic to detect tumor somatic mutations, with multiple ctDNA-targeted sequencing panels commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide targeted therapy options. More recently, it has been appreciated that ctDNA fragmentation patterns are influenced by the chromatin structure of the cell of origin, with greater diversity in fragment size in areas with open chromatin and less diversity in fragment size in areas with closed chromatin. In consequence, multiple studies have found that ctDNA fragmentation patterns can be used to accurately infer epigenomic and transcriptomic phenotypes from their tumor cells of origin. However, these analyses have previously relied on whole-genome sequencing (WGS), and it is not feasible to identify FDA-approved biomarker indications in a cost-effective manner with WGS. Methods: Peripheral blood was collected from a cohort of 90 patients with metastatic HER2-negative breast cancer (ER-positive n=71, ER-negative n=19). Cell-free DNA was extracted from plasma and sequenced using a custom 822 gene pan-cancer targeted sequencing panel (IDT). Shannon entropy of first coding exon fragment sizes (E1SE) was used to quantify fragmentation patterns. Higher diversity of fragment sizes, leading to a higher E1SE, are expected in ctDNA derived from areas of the genome with more open chromatin. A machine learning model utilizing the E1SE metric across all genes in the targeted panel was developed to distinguish between ER-positive and ER-negative disease. Results: Training cross-validated accuracy of the machine learning model was 87.8% with AUC of 0.91 to distinguish between ER-positive and ER-negative disease, despite a median ctDNA fraction of only 0.02. E1SE metrics for ESR1 and CCND1 were significantly higher in ER-positive than ER-negative samples, while E1SE metrics for EGFR, c-Kit and members of the MAP kinase family were significantly higher in ER-negative than ER-positive samples, consistent with anticipated differences in gene expression between ER-positive and ER-negative triple negative breast cancers. In contrast, HER2 E1SE was similar between groups, as expected in this clinically HER2-negative cohort. Conclusions: We have shown for the first time that sequencing from standard targeted ctDNA panels can be utilized to infer phenotypic information through analysis of ctDNA fragmentation patterns in patients with metastatic breast cancer. This expands the depth of potential biologic data that can be extracted from targeted ctDNA sequencing panels in addition to DNA mutation status in a cost-effective manner. In the future, this approach can be exploited to expand ctDNA-based biomarker development beyond DNA mutation status. Citation Format: Kyle Helzer, Jamie Sperger, Yue Shi, Viridiana Carreno, Hannah Krause, Katherine Kaufmann, Leilani Mora-Rodriguez, Matthew Bootsma, Mark Burkard, Ruth O'Regan, Kari Wisinski, Joshua Lang, Shuang (George) Zhao, Malinda West, Marina Sharifi. Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PS06-09.

oncology
Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects

Hao Liao,Wenfa Huang,Wendi Pei,Huiping Li

DOI: https://doi.org/10.3389/fonc.2020.587671

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Endocrine therapy is the main treatment option for estrogen receptor-positive (ER+) breast cancer (BC). Compared with other clinical subtypes, ER+ BC patients usually have a more favorable prognosis. However, almost all ER+ BCpatients develop endocrine resistance and disease progression eventually. A large number of studies based on liquid biopsy suggest that ESR1 mutations may play a key role in this process. For patients with ER+ metastatic BC (MBC), ESR1 is an important prognostic factor and may associate with the resistance to endocrine therapy, like aromatase inhibitors. The advances of sequencing technologies allow us to conduct longitudinal monitoring of disease and unveil the clinical implications of each ESR1 sub-clone in ER+ MBC. Moreover, since the ESR1-related endocrine resistance has not been fully addressed by existing agents, more potent cornerstone drugs should be developed as soon as possible. Herein, we reviewed the recent progress of detecting ESR1 mutations based on liquid biopsy and different sequencing technologies in ER+ MBC and discussed its clinical impacts and prospects.
Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS)

Lorenzo Gerratana,Andrew A Davis,Marko Velimirovic,Katherine Clifton,Whitney L Hensing,Ami N Shah,Charles S Dai,Carolina Reduzzi,Paolo D’Amico,Qiang Zhang,Firas Wehbe,Seth Wander,William J Gradishar,Amir Behdad,Fabio Puglisi,Cynthia X Ma,Aditya Bardia,Massimo Cristofanilli

DOI: https://doi.org/10.1158/1538-7445.sabcs21-pd6-08

IF: 11.2

2022-02-15

Cancer Research

Abstract:Abstract Background: High throughput genomic technologies such as NGS are enhancing the ability to dynamically characterize MBC but their role in describing biological evolution of multiple mutations together remains unclear. ESR1 and PIK3CA are central mutations related to the biology and druggability of hormone-receptor positive, HER2 negative (luminal-like) MBC. The aim of this study was to explore the interplay between oncogenic pathway alterations and ESR1 and PIK3CA codon variants on the impact and clinical phenotype of luminal-like MBC. Methods: The study retrospectively analyzed a multi-institutional cohort comprising 1047 MBC patients (pts) characterized for ctDNA through NGS before treatment start at Northwestern University (Chicago, IL), Massachusetts General Hospital (Boston, MA) and Washington University in St. Louis between 2015-2020. The analysis was then focused on luminal-like MBC. Pathway classification was defined based on previous work (Sanchez-Vega F et al, Cell. 2018) (i.e., RTK, RAS, RAF, MEK, NRF2, ER, WNT, MYC, P53, cell cycle, notch, PI3K). Single nucleotide variations (SNVs) were annotated for their oncogenicity through OncoKB and ClinVar. Only pathogenic variants were included in the models. Associations among, pathway classification, and ESR1/PIK3CA codon variants were explored through stepwise logistic regression. Overall survival (OS) was tested through Cox regression. Results: The luminal-like cohort comprised 702 pts. ESR1 mutations were detected in 166 pts (24%) and PIK3CA in 214 pts (31%). The most common ESR1 gene mutations were found in codons 537 (31%), 538 (21%), 536 (8%) and 380 (7%), while alterations in codons 1047 (38%), 545 (25%), and 542 (20%) were the most common for PIK3CA. Other pathogenic SNVs were observed in 33% and 17% of pts for ESR1 and PIK3CA, respectively with the former being polyclonal. SNVs alterations were mainly observed in the PI3K (35%), P53 (32%), ER (28%), RAS (8%), RTK (8%) and cell cycle (5%) pathways, while copy number variations (CNVs) were detected in the RTK (15%), cell cycle (11%), MYC (7%) PI3K (6%) and RAF (5%) pathways. ESR1 537 variants were associated with alterations in the ER and WNT pathways, 538 with cell cycle, 380 with P53 and ER, 536 with RTK. PIK3CA 1047 variants were associated with alterations in the RTK and P53 pathways, 542 with RTK, RAS and RAF, E545 with PI3K, RAS, cell cycle and P53. 1047 and 542 were also associated with CNVs in the PI3K pathway. Independent prognostic factors in terms of OS were ESR1 537/380 codon variants (HR 1.94 P = 0.001 and HR 2.29 P = 0.047), SNVs in the RAS, cell cycle, and P53 pathways (HR 1.74 P = 0.003 HR 1.84 P = 0.009 and HR 1.56 P < 0.001) and CNVs in the cell cycle pathway (HR 1.96 P < 0.001). Conclusions: This study demonstrated how ESR1 and PIK3CA codon variants, together with alterations in specific oncogenic pathways, can differentially impact the biology and clinical phenotype of luminal-like MBC. As novel endocrine therapy agents such as selective estrogen receptor degraders (SERDs) and PI3K inhibitors are being developed, these results highlight the pivotal role of ctDNA NGS to describe tumor evolution and optimize clinical decision making. Odds Ratio95% Confidence IntervalPESR1 Y537ER SNVs3.341.487.530.004WNT SNVs6.251.4127.740.016ESR1 D538cell cycle SNVs5.221.7915.230.003ESR1 E380P53 SNVs4.801.4116.310.012ER SNVs5.331.3321.400.018ESR1 L536RTK CNVs4.511.1517.690.031PIK3CA H1047RTK SNVs3.751.708.290.001P53 SNVs2.611.584.34< 0.001PI3K CNVs6.082.4515.08< 0.001PIK3CA E542RTK SNVs5.001.9412.880.001RAS SNVs3.651.369.770.01RAF SNVs6.011.0733.870.042PI3K CNVs6.302.2917.36< 0.001PIK3CA E545PI3K SNVs2.881.276.530.011RAS SNVs2.871.186.980.02cell cycle SNVs3.071.088.740.035NRF2 SNVs21.431.29356.520.033P53 SNVs3.752.046.89< 0.001 Citation Format: Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Katherine Clifton, Whitney L Hensing, Ami N Shah, Charles S Dai, Carolina Reduzzi, Paolo D’Amico, Qiang Zhang, Firas Wehbe, Seth Wander, William J Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli. Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD6-08.

oncology
Abstract 2429: Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2− breast cancer receiving endocrine therapy and CDK4/6 inhibitors

Jesus Fuentes-Antras,Mitchell J. Elliott,Philippe Echelard,Aaron Dou,Zachary Veitch,Philippe L. Bedard,Eitan Amir,Michelle B. Nadler,Nicholas Meti,Nancy Gregorio,Elizabeth Shah,Emily Van de Laar,Celeste Yu,Lisa Gates,Clodagh Murray,Christopher G. Smith,Amber Chevalier,Lillian L. Siu,Hal K. Berman,David W. Cescon

DOI: https://doi.org/10.1158/1538-7445.am2024-2429

IF: 11.2

2024-03-28

Cancer Research

Abstract:BACKGROUND: ctDNA burden is prognostic and its dynamics during therapy may permit innovative strategies in metastatic breast cancer (mBC). Previous analyses have focused on driver genes, with limited sensitivity to quantify depth of response or detect early molecular progression. To enable sensitive, quantitative ctDNA monitoring, we analyzed samples from a cohort of HR+/HER2− mBC pts treated with endocrine therapy (ET) and CDK4/6 inhibitors (CDKi) using RaDaR, a patient-specific assay that tracks tumor-informed truncal variants independent of driver status with a limit of detection of 0.001%. METHODS: HR+/HER2− mBC pts receiving standard ET + CDKi were enrolled in a prospective observational cohort from 2018. Plasma samples were collected at baseline (BL), within 30 days (d), and ~q3 months (mo) with radiological scans. RaDaR was performed on all samples for pts with tissue available for WES (as per assay). Clinico-pathological variables were collected. Endpoints were time to treatment failure (TTF) and overall survival (OS). RESULTS: 51 pts were available for analysis. Median age was 60 years (range 38-88), 63% had visceral disease, and most pts were treated as first (75%) or second (20%) line. RaDaR was successful on 43 pts, with the rest dropping out due to failed WES (1) or panel failure (7). Archival tissue WES was used to design bespoke assays targeting a median 48 (23-52) variants in 248 samples, with a median of 5 samples/pt (2-14) collected over a median follow up of 27.8 (0.9-64.3) mo. ctDNA was detected in 91% (39/43) of BL and 70% (174/248) of all samples, with a median estimated variant allele fraction (eVAF) of 0.05%. Higher BL eVAFs were associated with liver disease (p=0.02) and with shorter TTF (p<0.01 adjusted by age and visceral disease) and OS (p<0.01). 36/39 pts had ≥1 sample with ctDNA decrease from BL, occurring within the first mo of therapy in 77% (24/31) of pts with available early samples. In 13 pts ctDNA became undetectable ('suppressed') at a median time (T) of 157 d (14-343). Among 25 pts with treatment failure (TF), the median T from the last negative/decreasing eVAF to TF was 163 d (0-943). Only 3 pts with TF had prior negative ctDNA, occurring with a median lead T of 198 d (119-595). Among ongoing pts, the median T from the last ctDNA decrease to last follow up was 317 d (163-1508), and from the last negative ctDNA sample was 352 d (163-993). CONCLUSION: RaDaR enabled sensitive ctDNA monitoring in 91% HR+/HER2− mBC pts on ET + CDK4/6i. ctDNA levels were prognostic and fell rapidly with therapy, but suppression occurred in less than one-third of pts, taking a median of 5.2 mo. Pts with negative/decreasing ctDNA may require less frequent clinical/radiographic tumor evaluations. Highly sensitive ctDNA tracking may inform prognostic assessments, follow up strategies, and innovative interventional trial designs. Citation Format: Jesus Fuentes-Antras, Mitchell J. Elliott, Philippe Echelard, Aaron Dou, Zachary Veitch, Philippe L. Bedard, Eitan Amir, Michelle B. Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Emily Van de Laar, Celeste Yu, Lisa Gates, Clodagh Murray, Christopher G. Smith, Amber Chevalier, Lillian L. Siu, Hal K. Berman, David W. Cescon. Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2− breast cancer receiving endocrine therapy and CDK4/6 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2429.

oncology
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies

Fernando Recio,Carly Bess Scalise,Paul Loar,Melissa Lumish,Tara Berman,Abhinand Peddada,Ekaterina Kalashnikova,Samuel Rivero-Hinojosa,Tricia Beisch,Brittany Nicosia,Tiffany Farmer,Punashi Dutta,Meenakshi Malhotra,Adam C ElNaggar,Minetta C Liu,Luis Vaccarello,Robert W Holloway

DOI: https://doi.org/10.1016/j.ygyno.2023.12.025

Abstract:Introduction: Among uterine malignancies, endometrial cancer (EC) is the most common cancer of the female reproductive tract. Traditionally, risk stratification in EC is determined by standard clinicopathological risk factors. Although circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker in various malignancies, its clinical validity in EC remains to be established. Methods: In this analysis of real-world data, 267 plasma samples from 101 patients with stage I EC were analyzed using a tumor-informed ctDNA assay (Signatera™ bespoke mPCR-NGS). Patients were followed post-surgically and monitored with ctDNA testing for a median of 6.8 months (range: 0.37-19.1). Results: Patients who tested ctDNA-positive at both their first time point and longitudinally experienced inferior recurrence-free survival (RFS) (HR = 6.2; p = 0.0006 and HR = 15.5; p < 0.0001, respectively), and showed a recurrence rate of 58% and 52%, vs. 6% and 0%, respectively for the ctDNA-negative patients. Most ctDNA-positive patients had high-risk histologies or sarcoma, versus low-risk and high-intermediate risk (H-IR) EC. Furthermore, patients with high-risk histologies who were ctDNA-positive showed shorter RFS compared to those who tested negative (HR = 9.5; p = 0.007), and those who tested positive in the low/H-IR cohort (HR = 0.25; p = 0.04). Post-surgically, detectable ctDNA was highly prognostic of clinical outcome and remained the only significant risk factor for recurrence when adjusted for clinicopathological risk factors, such as histologic risk group, mismatch repair (MMR), and p53 status. Conclusion: Incorporating ctDNA monitoring along with traditional known risk factors may aid in identifying patients with stage I EC who are at highest risk of recurrence, and possibly aid in treatment stratification.
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors

Alessandra Virga,Caterina Gianni,Michela Palleschi,Davide Angeli,Filippo Merloni,Roberta Maltoni,Paola Ulivi,Giovanni Martinelli,Ugo De Giorgi,Sara Bravaccini

DOI: https://doi.org/10.3390/biomedicines12102183

IF: 4.757

2024-09-27

Biomedicines

Abstract:Background: Patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) generally receive hormonal therapy (HT) combined with CDK4/6 inhibitors (CDK4/6i). Despite this treatment, resistance mechanisms to CDK4/6i emerge and the majority of these patients experience disease progression (PD). This highlight the necessity to uncover the resistance mechanism to CDK4/6i through the identification of specific biomarkers. The primary objective is to assess the accuracy and feasibility of a novel multi-gene target panel NGS assay on circulating tumor DNA (ctDNA) to detect molecular alterations of AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 genes in women with BC undergoing HT plus CDK4/6i treatment. Secondarily, the study aims to explore the relationship between genomic profiling and clinical outcomes. Materials and Methods: Plasma samples were collected from 16 patients diagnosed with advanced/locally advanced HR+/HER2- BC at 2 time points: T0 (baseline) and at T1 (3 months after CDK4/6i treatment). Starting from 2 mL of plasma, ctDNA was isolated and libraries were set up using the Plasma-SeqSensei (PQS)® Breast Cancer IVD Kit, sequenced on Nextseq 550 and analyzed using the Plasma-SeqSenseiTM IVD Software®. Results: Among the five patients who presented PD, three had PIK3CA mutations and, of these, two showed a higher mutant allele frequency (MAF) at T1. In three patients with stable disease and in eight patients with partial response, the MAF of the detected alterations decreased dramatically or disappeared during CDK4/6i treatment. Conclusions: Based on our findings, the liquid biopsy analysis using the PQS panel seems to be both feasible and accurate, demonstrating a strong sensitivity in detecting mutations. This exploratory analysis of the clinical outcome associated to the mutational status of patients highlights the potential of molecular analysis on liquid biopsy for disease monitoring, although further validation with a larger patient cohort is necessary to confirm these preliminary observations.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry.

Angel Guerrero,Isabel Alvarez,Silvia Antolín Novoa,Josefina Cruz Jurado,CESAR Augusto Rodriguez Sanchez,Purificacion Martinez,Catalina Falo,María Hernández-Sosa,Mireia Margelí,Iria Gonzalez Maeso,Álvaro Rodríguez- Lescure,Maria Marin Alcalá,Antonio Anton,Silvia Varela Ferreiro,Jesús Herranz,Rosalia Caballero,Daniel Fernández García,Ariadna Tibau,Sara Lopez-Tarruella Cobo,Federico Gustavo Rojo Todo

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1011

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:1011 Background: Patients (pts) with hormone receptor-positive (HR) early breast cancer (BC) may develop resistance to adjuvant endocrine therapies (ET), with relapse occurring months (m) to decades after surgery. Our study explores clinical characteristics, prognosis, and oncogenic drivers in circulating tumor DNA (ctDNA) at relapse in HR+ BC pts, based on their sensitivity to adjuvant ET. Methods: In the REGISTEM study, we identified 805 primary HR-positive BC pts who developed metastatic relapse. These cases were classified based on their sensitivity to adjuvant ET, according to the 5th ESO-ESMO ABC Guidelines: 1ET-resistance (1ET-R, relapse within the first 2 years of adj ET; n=138), 2ET-resistance (2ET-R, relapse after the first 2 years or 12 m of completing adj ET; n=383). Out of this cohort, 139 individuals had plasma samples obtained prior to the initiation of the first-line treatment for advanced disease, and these samples were analyzed using the AVENIO ctDNA assay. Results: Pts with 1ET-R were significantly more likely to have grade 3, stage III, and highly proliferative tumors (Ki67>20%). The median time to distant relapse was 24 m for 1ET-R, 52.8 m for 2ET-R, and 124 m for ET-S cases. For first-line treatment, the median PFS was 8.1 m for 1ET-R, 13 m for 2ET-R, and 21.2 m for ET-S relapse (p<0.0001). With a median follow-up in the advanced setting of 34 m, median OS was 28 m for 1ET-R, 46 m for 2ET-R, and 55 m for ET-S relapses (p<0.0001). Pts with ET resistance had more mutations (mut) and higher mut allele frequency than ET-sensitive relapse. Pts with ET resistance showed higher incidence of mut in TP53, ESR1, PTEN, andhigh copy number in EGFRand ERBB2 than ET-sensitive, but similar incidence of mut in PIK3CA.Mut in ESR1 and high copy number in EGFR were correlated with poorer PFS, while ESR1 mut were additionally associated with worse OS, although these associations were not independent of the ET relapse groups (Table). Furthermore, mut in PIK3CA were associated to worse PFS only in ET-R pts. Conclusions: In HR-positive BC, both primary and secondary resistance to adjuvant ET represents a highly aggressive disease with enriched actionable genetic alterations detected at the time of diagnosis of metastatic relapse. Addressing these alterations has the potential to mitigate the unfavorable prognosis associated with these cases. Clinical trial information: NCT02819882 .[Table: see text]

oncology

Enzymatic generation of whey protein hydrolysates under pH-controlled and non pH-controlled conditions: Impact on physicochemical and bioactive properties.

Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).

Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.

Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Diagnostic utility of ESR1 mutation detection in liquid biopsy of metastatic breast cancer patients

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).

Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial

ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).

THE ART OF NURSING

Leucine metabolism in rats with cirrhosis.

Abstract 3676: A circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer

Abstract PS06-09: Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies

Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects

Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS)

Abstract 2429: Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2− breast cancer receiving endocrine therapy and CDK4/6 inhibitors

Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies

A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors

Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry.